MDX2001 not checked

ModeX Therapeutics, An OPKO Health Company

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
MET · TROP2 · CD3 · CD28
 

What this is

How it works
How it works isn't classified yet
How it’s given
“MDX2001 intravenous infusion or subcutaneous (SC) injection.”In the company’s words, NCT06239194 on ClinicalTrials.gov
Tested for
Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer and 13 more
Main trialPhase 1/2
“This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.”In the company’s words, NCT06239194 on ClinicalTrials.gov

Other drugs for Biliary Tract Cancer

All 78 drugs for Biliary Tract Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Aug 2028 Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MDX2001

Following is part of Solo: you see every change to MDX2001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in